

ACI Formulations Limited

**3rd Quarter ended Report 2020-2021
for the nine months ended on 31 March 2021**


ACI Formulations Limited

Statement of financial position
Unaudited


Figures in "000"

<i>In Taka</i>	Note	As at 31 March 2021	As at 30 June 2020
Assets			
Property, plant and equipment	5	1,876,432	1,902,608
Right-of-use assets		5,749	12,118
Investments	6	39,765	39,765
Non-current assets		1,921,946	1,954,491
Inventories	8	1,273,872	1,270,805
Trade receivables	9	1,672,905	1,574,240
Other receivables		53,207	40,678
Inter-company receivables	10	8,518	25,404
Advances, deposits and prepayments	11	49,764	79,424
Current tax assets		337,650	323,894
Cash and cash equivalents		153,478	248,676
Current assets		3,549,394	3,563,121
Total assets		5,471,340	5,517,612
Equity			
Share capital		450,000	450,000
Revaluation reserve		1,136,393	1,136,393
Retained earnings		911,685	820,348
Total equity		2,498,078	2,406,741
Liabilities			
Employee benefits	12	55,178	48,492
Deferred tax liabilities		17,358	24,686
Lease liabilities		1,783	4,386
Non-current liabilities		74,319	77,564
Bank overdrafts		78,376	76,793
Loans and borrowings		1,798,075	1,626,971
Lease liabilities- current portion		4,235	6,613
Trade payables		75,519	118,584
Other payables	13	425,401	340,242
Inter-company payables	14	517,337	864,104
Current liabilities		2,898,943	3,033,307
Total liabilities		2,973,262	3,110,871
Total equity and liabilities		5,471,340	5,517,612
Net asset value (NAV) per share		55.51	53.48


Managing Director


Director


Chief Financial Officer


Company Secretary


ACI Formulations Limited

Statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the nine months period ended from		For the 3rd quarter ended from	
		July 2020 to March 2021	July 2019 to March 2020	January 2021 to March 2021	January 2020 to March 2020
Revenue	15	3,016,132	2,598,571	1,102,620	943,120
Cost of sales	16	(2,134,510)	(1,700,365)	(781,470)	(600,292)
Gross profit		881,622	898,206	321,150	342,828
Other income		2,600	3,983	739	1,074
Administrative, selling and distribution expenses	17	(518,985)	(607,042)	(189,433)	(244,381)
Operating profit		365,237	295,147	132,456	99,521
Finance costs, net		(102,814)	(178,293)	(31,691)	(58,362)
Profit before contribution to WPPF		262,423	116,854	100,765	41,159
Contribution to WPPF		(13,121)	(5,843)	(5,038)	(2,058)
Profit before tax		249,302	111,011	95,727	39,101
Tax expenses		(67,965)	(29,563)	(25,694)	(10,134)
Profit after tax		181,337	81,447	70,033	28,966
Other comprehensive income		-	-	-	-
Total comprehensive income		181,337	81,447	70,033	28,966
Earnings per share					
Basic earnings per share (BEPS)		4.03	1.81	1.56	0.64


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited
Statement of changes in equity
Unaudited

Figures in "000"

<i>In Taka</i>	For the nine months period ended 31 March 2021			
	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2020	450,000	1,136,393	820,348	2,406,741
Total comprehensive income				
Profit for the period	-	-	181,337	181,337
Total comprehensive income	-	-	181,337	181,337
Transactions with owners of the company				
Contributions and distributions				
Final dividend for the year 2019-20	-	-	(90,000)	(90,000)
Total transactions with owners of the company	-	-	(90,000)	(90,000)
Balance at 31 March 2021	450,000	1,136,393	911,685	2,498,078

<i>In Taka</i>	For the nine months period ended 31 March 2020			
	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2019	450,000	1,136,393	885,396	2,471,789
Total comprehensive income				
Profit for the period	-	-	81,447	81,447
Total comprehensive income	-	-	81,447	81,447
Transactions with owners of the company				
Contributions and distributions				
Final dividend for the year 2018-19	-	-	(157,500)	(157,500)
Total transactions with owners of the company	-	-	(157,500)	(157,500)
Balance at 31 March 2020	450,000	1,136,393	809,343	2,395,736

ACI Formulations Limited

Statement of cash flows
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the nine months period ended from	
		July 2020 to March 2021	July 2019 to March 2020
Cash flows from operating activities			
Cash received from customers and others		2,907,105	2,499,130
Cash paid to suppliers and employees		(2,536,187)	(1,710,863)
Cash (used in)/generated from operating activities		370,918	788,267
Payment for WPPF		(6,609)	(9,553)
Interest paid		(108,487)	(146,534)
Income tax paid		(89,048)	(88,876)
		(204,144)	(244,963)
Net cash (used in)/generated from operating activities*	18	166,774	543,304
Cash flows from investing activities			
Acquisition of property, plant and equipment		(10,221)	(22,598)
Net cash (used in)/generated from investing activities		(10,221)	(22,598)
Cash flows from financing activities			
Inter-company debts received/(paid)		(329,881)	(148,299)
Proceeds from loans and borrowings		171,103	(342,331)
Payment for lease liability		(4,981)	(6,025)
Dividends paid		(89,575)	(151,523)
Net cash (used in)/generated from financing activities		(253,334)	(648,178)
Net increase in cash and cash equivalents		(96,781)	(127,472)
Cash and cash equivalents as at 1 July		171,883	168,949
Cash and cash equivalents as at 31st March		75,102	41,477
Closing balance represents			
Cash and cash equivalents		153,478	137,191
Bank overdraft		(78,376)	(95,714)
		75,102	41,477
Net operating cash flow per share (NOCFPS)		3.71	12.07

* See Note 18 for reconciliation of net operating cash flow.

ACI Formulations Limited
Consolidated Statement of Financial Position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 31 March 2021	As at 30 June 2020
Assets			
Property, plant and equipment	5(a)	1,877,532	1,903,985
Right-of-use assets		5,749	12,118
Investments	6(a)	35,817	35,817
Intangible assets	7	5,148	5,148
Non-current assets		1,924,246	1,957,068
Inventories	8(a)	1,273,872	1,270,805
Trade receivables	9(a)	1,673,737	1,575,246
Other receivables		53,315	40,619
Inter-company receivable	10(a)	1,671	17,863
Advances, deposits and prepayments	11(a)	50,461	80,121
Current tax assets		337,416	323,758
Cash and cash equivalents		154,274	249,369
Current assets		3,544,746	3,557,781
Total assets		5,468,992	5,514,849
Equity			
Share capital		450,000	450,000
Revaluation reserve		1,136,393	1,136,393
Retained earnings		907,331	815,586
Equity attributable to the owner of the Company		2,493,724	2,401,979
Non controlling interest		(114)	(122)
Total equity		2,493,610	2,401,857
Liabilities			
Employee benefits	12	55,178	48,492
Deferred tax liabilities		17,266	24,595
Lease liabilities		1,783	4,386
Non-current liabilities		74,227	77,473
Bank overdrafts		78,376	76,794
Loans and borrowings		1,798,076	1,626,971
Lease liabilities- current portion		4,235	6,613
Trade payables		76,899	119,963
Other payables	13(a)	426,232	341,074
Inter-company payables	14	517,337	864,104
Current liabilities		2,901,155	3,035,519
Total liabilities		2,975,382	3,112,992
Total equity and liabilities		5,468,992	5,514,849
Net asset value (NAV) per share	19	55.42	53.38


 Managing Director


 Director


 Chief Financial Officer


 Company Secretary


ACI Formulations Limited

Consolidated statement of profit or loss and other comprehensive income
Unaudited


Figures in "000"

In Taka	Note	For the nine months period ended from		For the 3rd quarter ended from	
		July 2020 to March 2021	July 2019 to March 2020	January 2021 to March 2021	January 2020 to March 2020
Revenue	15(a)	3,017,101	2,599,764	1,102,874	943,708
Cost of sales	16(a)	(2,134,510)	(1,700,364)	(781,470)	(600,290)
Gross profit		882,591	899,400	321,404	343,418
Other income		2,600	3,983	739	1,074
Administrative, selling and distribution expenses	17(a)	(519,174)	(607,428)	(189,427)	(244,491)
Operating profit		366,017	295,955	132,716	100,001
Finance costs, net		(103,081)	(178,293)	(31,815)	(58,362)
Profit before contribution to WPPF		262,936	117,662	100,902	41,639
Contribution to WPPF		(13,121)	(5,843)	(5,038)	(2,058)
Profit before tax		249,815	111,819	95,864	39,581
Income tax expenses		(68,062)	(29,682)	(25,720)	(10,194)
Profit after tax		181,753	82,136	70,144	29,387
Other comprehensive income		-	-	-	-
Total comprehensive income		181,753	82,136	70,144	29,387
Total comprehensive income attributable to:					
Owners of the Company		181,745	82,122	70,142	29,378
Non controlling interest		8	14	2	9
		181,753	82,136	70,144	29,387
Earnings per share					
Basic earnings per share (BEPS)	19	4.04	1.82	1.56	0.65


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity
Unaudited

Figures in '000"

For the nine months period ended 31 March 2021

<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2020	450,000	1,136,393	815,586	2,401,979	(122)	2,401,857
Total comprehensive income						
Profit for the period	-	-	181,745	181,745	8	181,753
Total comprehensive income	-	-	181,745	181,745	8	181,753
Transactions with owners of the company						
Contributions and distributions						
Final dividend for the year 2019-20	-	-	(90,000)	(90,000)	-	(90,000)
Total transactions with owners of the company	-	-	(90,000)	(90,000)	-	(90,000)
Balance at 31 March 2021	450,000	1,136,393	907,331	2,493,724	(114)	2,493,610

For the nine months period ended 31 March 2020

<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2019	450,000	1,136,393	880,352	2,466,745	(127)	2,466,618
Total comprehensive income						
Profit for the period	-	-	82,122	82,122	14	82,136
Total comprehensive income	-	-	82,122	82,122	14	82,136
Transactions with owners of the company						
Contributions and distributions						
Final dividend for the year 2018-19	-	-	(157,500)	(157,500)	-	(157,500)
Total transactions with owners of the company	-	-	(157,500)	(157,500)	-	(157,500)
Balance at 31 March 2020	450,000	1,136,393	804,974	2,391,367	(113)	2,391,254

ACI Formulations Limited
Consolidated statement of cash flows
Unaudited

<i>In Taka</i>	Note	Figures in '000"	
		For the nine months period ended from	
		July 2020 to March 2021	July 2019 to March 2020
Cash flows from operating activities			
Cash received from customers and others		2,905,680	2,503,234
Cash paid to suppliers and employees		(2,533,639)	(1,714,311)
Cash (used in)/generated from operating activities		372,041	788,923
Payment for WPPF		(6,609)	(9,553)
Interest paid		(108,753)	(146,534)
Income tax paid		(89,048)	(88,943)
		(204,410)	(245,030)
Net cash (used in)/generated from operating activities*	18 (a)	167,631	543,893
Cash flows from investing activities			
Acquisition of property, plant and equipment		(10,221)	(22,598)
Net cash (used in)/generated from investing activities		(10,221)	(22,598)
Cash flows from financing activities			
Inter-company debts received/(paid)		(330,634)	(146,927)
Proceeds from loans and borrowings		171,103	(344,168)
Payment for lease liability		(4,981)	(6,025)
Dividends paid		(89,575)	(151,523)
Net cash (used in)/generated from financing activities		(254,087)	(648,643)
Net increase in cash and cash equivalents		(96,677)	(127,348)
Cash and cash equivalents as at 1 July		172,575	169,896
Cash and cash equivalents as at 31st March		75,898	42,548
Closing balance represents			
Cash and cash equivalents		154,274	138,262
Bank overdraft		(78,376)	(95,714)
		75,898	42,548
Net operating cash flow per share (NOCFPS)	19	3.73	12.09

* See Note 18(a) for reconciliation of consolidated net operating cash flow.

ACI Formulations Limited

Notes to the financial statements as at and for the nine months period ended on 31 March 2021 Unaudited

1 **Company profile:**

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

2 **Subsidiaries of ACI Formulations Limited:**

ACI Formulations Limited has one subsidiary namely Neem Laboratories (Pvt.) Ltd, engaged in manufacturing and marketing of herbal products . ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

3 **Consolidated Financial statements:**

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

4 **Selected explanatory notes:**

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2020. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

		Figures in '000'	
		<u>31- March -21</u>	<u>30-June -20</u>
		<u>Taka</u>	<u>Taka</u>
5	Property, plant & equipment		
	Opening balance	2,179,120	2,156,021
	Addition during the period/year	9,866	23,099
		<u>2,188,986</u>	<u>2,179,120</u>
	Accumulated depreciation at the end of period/year	<u>(312,554)</u>	<u>(276,512)</u>
	Closing balance	<u>1,876,432</u>	<u>1,902,608</u>
5(a)	Consolidated property, plant & equipment		
	Opening balance	2,184,080	2,160,981
	Addition during the period/year	9,866	23,099
		<u>2,193,946</u>	<u>2,184,080</u>
	Accumulated depreciation at the end of period/year	<u>(316,414)</u>	<u>(280,095)</u>
	Closing balance	<u>1,877,532</u>	<u>1,903,985</u>
6	Investments		
	Investment in subsidiaries	3,948	3,948
	Investment in FDR	35,742	35,742
	Investment in shares of ACI Motors Limited	75	75
		<u>39,765</u>	<u>39,765</u>

	<u>31- March -21</u>	<u>30-June -20</u>
	<u>Taka</u>	<u>Taka</u>
6(a) Consolidated investments		
Investment in FDR	35,742	35,742
Investment in Shares- ACI Motors Limited	75	75
	<u>35,817</u>	<u>35,817</u>
7 Intangible assets		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
8 Inventories		
Raw and packing materials	541,900	535,479
Work in process	609	3,802
Finished goods	567,047	588,585
Goods in transit	175,546	143,045
Other inventories	24,548	25,566
Allowances for slow moving inventory	(35,778)	(25,673)
	<u>1,273,872</u>	<u>1,270,805</u>
8(a) Consolidated inventories		
Raw and packing materials	541,900	535,479
Work in process	609	3,802
Finished goods	567,323	588,862
Goods in transit	175,546	143,045
Other inventories	24,548	25,566
Allowances for slow moving inventory	(36,054)	(25,949)
	<u>1,273,872</u>	<u>1,270,805</u>
9 Trade receivables:		
Related parties	-	-
Other than related parties	1,853,467	1,751,275
	<u>1,853,467</u>	<u>1,751,275</u>
Allowances for doubtful debts	(180,562)	(177,034)
	<u>1,672,905</u>	<u>1,574,240</u>
Below six months	1,474,334	1,327,222
Over six months	379,133	424,052
Allowances for doubtful debts	(180,562)	(177,034)
	<u>1,672,905</u>	<u>1,574,240</u>
9(a) Consolidated trade receivables		
Related parties	-	-
Other than related parties	1,854,299	1,752,280
	<u>1,854,299</u>	<u>1,752,280</u>
Allowances for doubtful debts	(180,562)	(177,034)
	<u>1,673,737</u>	<u>1,575,246</u>
Below six months	1,475,166	1,328,228
Over six months	379,133	424,052
Allowances for doubtful debts	(180,562)	(177,034)
	<u>1,673,737</u>	<u>1,575,246</u>

		<u>31- March -21</u> <u>Taka</u>	<u>30-June -20</u> <u>Taka</u>
10	Inter-company receivables		
	Neem Laboratories (Pvt.) Ltd.	8,518	25,404
		<u>8,518</u>	<u>25,404</u>
10(a)	Consolidated inter-company receivables		
	ACI Limited	1,671	17,863
		<u>1,671</u>	<u>17,863</u>
11	Advances, deposits & prepayments		
	Advances:		
	Staffs	508	219
	Suppliers & others	39,384	38,489
	VAT current account	(9,547)	18,776
		<u>30,345</u>	<u>57,484</u>
	Deposits:		
	Security deposits	9,227	12,712
	Bank guarantee margin	4,784	4,784
		<u>14,011</u>	<u>17,496</u>
	Prepayments:		
	Prepaid expenses	5,408	4,444
		<u>5,408</u>	<u>4,444</u>
		<u>49,764</u>	<u>79,424</u>
11(a)	Consolidated advances, deposits & prepayments		
	Advances:		
	Staff	508	219
	Suppliers & others	40,081	39,186
	VAT current account	(9,547)	18,776
		<u>31,042</u>	<u>58,181</u>
	Deposits:		
	Security deposits	9,227	12,712
	Bank guarantee margin	4,784	4,784
		<u>14,011</u>	<u>17,496</u>
	Prepayments:		
	Prepaid expenses	5,408	4,444
		<u>5,408</u>	<u>4,444</u>
		<u>50,461</u>	<u>80,121</u>
12	Employee benefits		
	Net defined benefit obligation	41,903	36,432
	Other employee benefits	13,275	12,060
		<u>55,178</u>	<u>48,492</u>

	<u>31- March -21</u> <u>Taka</u>	<u>30-June -20</u> <u>Taka</u>
13	Other payables	
	Creditor for expenses	273,199
	Advance from customer	4,199
	Interest payable	20,532
	Security money payable	16,246
	Unpaid dividend	12,580
	Withholding tax and VAT payable	6,877
	Workers' profit participation fund	6,609
	425,401	340,242
13(a)	Consolidated other payables	
	Creditor for expenses	273,859
	Advance from customer	4,199
	Interest payable	20,532
	Security money payable	16,246
	Unpaid dividend	12,580
	Withholding tax and VAT payable	7,049
	Provision for workers' profit participation fund	6,609
	426,232	341,074
14	Inter-company payables	
	ACI Limited	864,104
	517,337	864,104

		for the nine months period ended from	
		July 2020 to	July 2019 to
		March 2021	March 2020
		Taka	Taka
15	Revenue		
	Crop Care & Public Health	2,374,723	2,006,806
	Mosquito Coil	18,965	9,616
	Aerosol	333,849	240,784
	Paint	197,788	329,042
	Others	90,807	12,323
		<u>3,016,132</u>	<u>2,598,571</u>
15(a)	Consolidated revenue		
	Crop Care & Public Health	2,374,723	2,006,806
	Mosquito Coil	18,965	9,616
	Aerosol	333,849	240,784
	Paint	197,788	329,042
	Others	91,776	13,516
		<u>3,017,101</u>	<u>2,599,764</u>
16	Cost of sales		
	Opening stock	1,127,866	1,547,323
	Purchase	1,974,981	1,065,175
		<u>3,102,847</u>	<u>2,612,498</u>
	Closing stock	(1,109,556)	(1,049,043)
		<u>1,993,291</u>	<u>1,563,455</u>
	Manufacturing expenses	141,219	136,910
		<u>2,134,510</u>	<u>1,700,365</u>
16(a)	Consolidated cost of sales		
	Opening stock	1,128,142	1,563,768
	Purchase	1,974,981	1,065,174
		<u>3,103,123</u>	<u>2,628,942</u>
	Stock transferred to ACI Limited	-	(15,498)
	Closing stock	(1,109,832)	(1,049,320)
		<u>1,993,291</u>	<u>1,564,124</u>
	Manufacturing expenses	141,219	136,240
		<u>2,134,510</u>	<u>1,700,364</u>
17	Administrative, selling and distribution expenses		
	Administrative expenses	110,191	117,353
	Distribution expenses	88,927	83,782
	Selling expenses	319,867	405,907
		<u>518,985</u>	<u>607,042</u>
17(a)	Consolidated administrative, selling and distribution expenses		
	Administrative expenses	110,380	117,739
	Distribution expenses	88,927	83,782
	Selling expenses	319,867	405,907
		<u>519,174</u>	<u>607,428</u>

18 Reconciliation of net operating cash flow

<i>In Taka</i>	for the nine months period ended from	
	July 2020 to March 2021	July 2019 to March 2020
Profit after tax	181,337	81,447
Adjustment for non cash items and others:		
- Depreciation and amortization	36,397	49,121
- Provisions	14,084	1,205
- Net finance cost	(5,672)	30,376
- Tax expense	(21,084)	(59,091)
- Contribution to WPPF	6,512	(3,699)
Changes in:		
- Inventories	(13,173)	498,176
- Trade and other receivables	(114,722)	(104,229)
- Advances, deposit and prepayments	29,661	15,249
- Trade and other payables, employment benefits ¹	53,434	34,749
Cash generating from operating activities	166,774	543,304

18 (a)

Reconciliation of consolidated net operating cash flow

<i>In Taka</i>	for the nine months period ended from	
	July 2020 to March 2021	July 2019 to March 2020
Profit after tax	181,753	82,136
Adjustment for:		
- Depreciation and amortization	36,490	49,399
- Bad debts and inventory loss/(recovery)	14,084	1,205
- Net finance cost	(5,672)	30,376
- Tax expense	(20,987)	(59,039)
- Contribution to WPPF	6,512	(3,699)
Changes in:		
- Inventories	(13,173)	500,011
- Trade and other receivables	(114,714)	(102,198)
- Advances, deposit and prepayments	29,661	16,087
- Trade and other payables, employment benefits ¹	53,677	29,615
Cash generating from operating activities	167,631	543,893

		for the nine months period ended from	
		July 2020 to	July 2019 to
		March 2021	March 2020
19	Consolidated EPS, NAV per Share and NOCFPS:		
	Weighted average number of ordinary shares (in	45,000	45,000
	Consolidated profit attributable to equity holders of the		
	Company (Taka '000)	181,745	82,122
	Earnings per share (Taka)	4.04	1.82
	Consolidated net asset attributable to equity holders of the	2,493,724	2,401,979
	Net asset value (NAV) per share	55.42	53.38
	Consolidated cash flows from operating activities (Taka	167,631	543,893
	Net operating cash flows per share (NOCFPS)	3.73	12.09

Reasons for significant deviations: The consolidated revenue grew by around 16% over SPLY propelled by higher sales mainly in CC&PH business. Moreover, effective control over operating expenses coupled with lower financing cost led to higher consolidated profit after tax against SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS decreased mainly due to inventory build-up for meeting the demand of upcoming quarter .

20 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

Crop Care and Public Health (CC & PH) To manufacture and sell crop care and public health products.

Mosquito Coil (M Coil) To manufacture and sell mosquito coil products

Aerosol To manufacture and sell aerosol and air freshener products.

Paint To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	for the nine months period ended		for the nine months period		for the nine months		for the nine months		for the nine months period		for the nine months period	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20	31-Mar-21	31-Mar-20
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	2,374,723	2,006,806	18,965	9,616	333,849	240,784	197,788	329,042	23,461	12,323	2,948,786	2,598,571
Inter-segment revenues	-	-	-	-	-	-	-	-	68,315	1,193	68,315	1,193
Total revenue	2,374,723	2,006,806	18,965	9,616	333,849	240,784	197,788	329,042	91,776	13,516	3,017,101	2,599,764
Financing costs	(89,511)	(147,823)	-	-	-	-	(13,052)	(29,087)	(518)	(1,383)	(103,081)	(178,293)
Depreciation	(15,149)	(24,482)	(13,265)	(15,087)	(3,678)	(4,424)	(3,711)	(4,472)	(765)	(932)	(36,568)	(49,397)
Cost of sales excluding depreciation	(1,520,032)	(1,223,785)	(39,872)	6,946	(305,992)	(186,684)	(154,874)	(252,980)	(87,900)	(8,352)	(2,108,671)	(1,664,855)
Operating expenses excluding depreciation	(412,353)	(478,501)	(4,594)	(6,957)	(5,854)	(7,454)	(85,577)	(100,495)	(68)	(133)	(508,445)	(593,540)
Other income /(expense)	1,856	2,933	-	-	36	375	708	675	-	-	2,600	3,983
Profit before tax	322,557	128,391	(36,828)	(5,208)	17,443	40,467	(55,781)	(54,451)	2,424	2,637	249,815	111,819
Reportable segment assets	2,805,341	2,802,759	686,062	708,443	702,630	685,821	422,706	441,225	852,253	876,601	5,468,992	5,514,849
Reportable segment liabilities	1,733,602	1,966,169	9,247	6,885	78,721	124,742	77,307	99,360	1,076,504	915,836	2,975,381	3,112,992

21 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.